Codelivery of zoledronic acid and double-stranded RNA from core-shell nanoparticles

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 137-145

  Chen, Li ^a   Ding, Yunfei ^b   Wang, Yongzhong ^c   Liu, Xingrong ^b   Babu, R J ^a   Ravis, W R ^a   Yan, Weili ^b  

^a AUBURN UNIVERSITY   (United States)

^b SOUTHWEST JIAOTONG UNIVERSITY   (China)

^c ANHUI UNIVERSITY   (China)

Author keywords

Calcium phosphate; Codelivery; Double stranded RNA; Lipid coated nanoparticles; Poly (I:C); Zoledronic acid

Indexed keywords

ALCOHOL; CALCIUM PHOSPHATE; NANOPARTICLE; POLYINOSINIC POLYCYTIDYLIC ACID; ZOLEDRONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MIXTURE; DRUG POTENTIATION; DRUG STABILITY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; ZETA POTENTIAL;

CALCIUM PHOSPHATE; CODELIVERY; DOUBLE-STRANDED RNA; LIPID-COATED NANOPARTICLES; POLY (I:C); ZOLEDRONIC ACID;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; DIPHOSPHONATES; DRUG STABILITY; FEMALE; IMIDAZOLES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NANOPARTICLES; PARTICLE SIZE; POLY I-C; RANDOM ALLOCATION; RNA, DOUBLE-STRANDED;

MUS;

EID: 84872289008     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S38928     Document Type: Article

References (58)

1. Aapro MS, Coleman RE. Bone health management in patients with breast cancer: current standards and emerging strategies. Breast. 2012;21(1):8-19.
2. Benzaid I, Monkkonen H, Stresing V, et al. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgam-ma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res. 2011;71(13):4562-4572.
3. Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 2001;61(6):2602-2608.
4. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer. 2000;82(8):1459-1468.
5. Clezardin P. Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class. Bone. 2011;48(1):71-79.
6. Giraduo E, Hanahan D. Zoledronic acid inhibits angiogenesis and impairs tumorigenesis in a mouse model of cervical carcinogenesis. Haematological Reports. 2006;3:39-41.
7. Almubarak H, Jones A, Chaisuparat R, Zhang M, Meiller TF, Scheper MA. Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers. J Carcinog. 2011;10:2.
8. Kunzmann V, Wilhelm M. Adjuvant zoledronic acid for breast cancer: mechanism of action? Lancet Oncol. 2011;12(11):991-992.
9. Cimini E, Piacentini P, Sacchi A, et al. Zoledronic acid enhances Vdelta2 T-lymphocyte antitumor response to human glioma cell lines. Int J Immunopathol Pharmacol. 2011;24(1):139-148.
10. Caraglia M, Marra M, Naviglio S, Botti G, Addeo R, Abbruzzese A. Zoledronic acid: an unending tale for an antiresorptive agent. Expert Opin Pharmacother. 2010;11(1):141-154.
11. Salzano G, Marra M, Porru M, et al. Self-assembly nanoparticles for the delivery of bisphosphonates into tumors. Int J Pharm. 2011;403(1-2):292-297.
12. Scheper M, Chaisuparat R, Cullen K, Meiller T. A novel soft-tissue in vitro model for bisphosphonate-associated osteonecrosis. Fibrogenesis Tissue Repair. 2010;3:6.
13. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3(1):16-20.
14. Agrati C, Marianecci C, Sennato S, et al. Multicompartment vectors as novel drug delivery systems: selective activation of Tγδ lymphocytes after zoledronic acid delivery. Nanomedicine. 2011;7:153-161.
15. van Rooijen N, van Kesteren-Hendrikx E. Clodronate liposomes: perspectives in research and therapeutics. J Liposome Res. 2002;12: 81-94.
16. Danenberg HD, Golomb G, Groothuis A, et al. Liposomal alendronate inhibits systemic innate immunity and reduces in-stent neointimal hyperplasia in rabbits. Circulation. 2003;108(22):2798-2804.
17. Marra M, Salzano G, Leonetti C, et al. Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. Nanomedicine. 2011;7(6):955-964.
18. Guo S, Huang L. Nanoparticles escaping RES and endosome: challenges for siRNA delivery for cancer therapy. J Nanomater. 2011:2011.
19. Hafner A, Corthesy B, Textor M, Merkle H. Tuning the immune response of dendritic cells to surface-assembled poly(I:C) on micro-spheres through synergistic interactions between phagocytic and TLR3 signaling. Biomaterials. 2011;32(10):2651-2661.
20. Zheng Y, An H, Yao M, et al. Scaffolding adaptor protein Gab1 is required for TLR3/4-and RIG-I-mediated production of proin-flammatory cytokines and type I IFN in macrophages. J Immunol. 2010;184(11):6447-6456.
21. Besch R, Poeck H, Hohenauer T, et al. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest. 2009;119(8):2399-2411.
22. Alonso-Curbelo D, Soengas MS. Self-killing of melanoma cells by cytosolic delivery of dsRNA: wiring innate immunity for a coordinated mobilization of endosomes, autophagosomes and the apoptotic machinery in tumor cells. Autophagy. 2010;6(1):148-150.
23. Cheng YS, Xu F. Anticancer function of polyinosinic-polycytidylic acid. Canc Biol Ther. 2011;10(12):1219-1223.
24. Tormo D, Checinska A, Alonso-Curbelo D, et al. Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells. Cancer Cell. 2009;16(2):103-114.
25. Jordan M, Schallhorn A, Wurm FM. Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. Nucleic Acid Res. 1996;24(4):596-601.
26. Li J, Chen YC, Tseng YC, Mozumdar S, Huang L. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Release. 2010;142(3):416-421.
27. Zhang M, Kataoka K. Nano-structured composites based on calcium phosphate for cellular delivery of therapeutic and diagnostic agents. Nanotoday. 2009;4(6):508-517.
28. Bisht S, Bhakta G, Mitra S, Maitra A. pDNA loaded calcium phosphate nanoparticles: highly efficient non-viral vector for gene delivery. Int J Pharm. 2005;288(1):157-168.
29. Sokolova VV, Radtke I, Heumann R, Epple M. Effective transfection of cells with multi-shell calcium phosphate-DNA nanoparticles. Biomaterials. 2006;27(16):3147-3153.
30. Silva C, Graca M, Sombra A, Valente M. Structural and electrical study of calcium phosphate obtained by a microwave radiation assisted procedure. Physica B Condens Matter. 2009;404(8-11):1503-1508.
31. Cho JS, Ko YN, Koo HY, Kang YC. Synthesis of nano-sized biphasic calcium phosphate ceramics with spherical shape by flame spray pyrolysis. J Mater Sci Mater Med. 2010;21(4):1143-1149.
32. Li K, Tjong SC. Hydrothermal synthesis and biocompatibility of hydroxy-apatite nanorods. J Nanosci Nanotechnol. 2011;11(12):10444-10448.
33. Xu HH, Moreau JL, Sun L, Chow LC. Nanocomposite containing amorphous calcium phosphate nanoparticles for caries inhibition. Dent Mater. 2011;27(8):762-769.
34. Thachepan S, Li M, Mann S. Mesoscale crystallization of calcium phosphate nanostructures in protein (casein) micelles. Nanoscale. 2010;2(11):2400-2405.
35. Dasgupta S, Bose S. Reverse micelle-mediated synthesis and characterization of tricalcium phosphate nanopowder for bone graft applications. J Am Ceram Soc. 2009;92(11):2528-2536.
36. Han J, Tan T, Loo J. Utilizing inverse micelles to synthesize calcium phosphate nanoparticles as nano-carriers. J Nanopart Res. 2011;13(8):3441-3454.
37. Shum H, Bandyopadhyay A, Bose S, Weitz D. Double emulsion droplets as microreactors for synthesis of mesoporous hydroxyapatite. Chem Mater. 2009;21(22):5548-5555.
38. Ergun C, Evis Z, Webster T, Sahin FC. Synthesis and microstructural characterization of nano-size calcium phosphates with different stoichiometry. Ceram Int. 2011;37:971-977.
39. Sokolova V, Knuschke T, Kovtun A, Buer J, Epple M, Westendorf A. The use of calcium phosphate nanoparticles encapsulating Toll-like receptor ligands and the antigen hemagglutinin to induce dendritic cell maturation and T cell activation. Biomaterials. 2010;31(21):5627-5633.
40. Zhou C, Yu B, Yang X, et al. Lipid-coated nano-calcium-phosphate (LNCP) for gene delivery. Int J Pharm. 2010;392(1-2):201-208.
41. Shmeeda H, Amitay Y, Gorin J, Tzemach D. Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells. J Control Release. 2010;146(1):76-83.
42. Marra M, Salzano G, Leonetti C, et al. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study. Biotechnol Adv. 2012;30(1):302-309.
43. Sudimack JJ, Guo W, Tjarks W, Lee RJ. A novel pH-sensitive liposome formulation containing oleyl alcohol. Biochim Biophys Acta. 2002;1564(1):31-37.
44. Kim CW, Yun YP, Lee HJ, Hwang YS, Kwon IK, Lee SC. In situ fabrication of alendronate-loaded calcium phosphate microspheres: controlled release for inhibition of osteoclastogenesis. J Control Release. 2010;147(1):45-53.
45. Cheng YS, Xu F. Anticancer function of polyinosinic-polycytidylic acid. Cancer Biol Ther. 2010;10:1219-1223.
46. Forte G, Rega A, Morello S, et al. Polyinosinic-polycytidylic acid limits tumor outgrowth in a mouse model of metastatic lung cancer. J Immunol. 2012;188(11):5357-5364.
47. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol. 2006; 176(8):4894-4901.
48. Hirabayashi K, Yano J, Inoue T, et al. Inhibition of cancer cell growth by polyinosinic-polycytidylic acid/cationic liposome complex: a new biological activity. Cancer Res. 1999;59(17):4325-4333.
49. Sokolova V, Epple M. Inorganic nanoparticles as carriers of nucleic acids into cells. Angew Chem Int Ed Engl. 2008;47(8):1382-1395.
50. Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology. 1973;52(2):456-467.
51. Shir A, Ogris M, Roedl W, Wagner E, Levitzki A. EGFR-homing dsRNA activates cancer-targeted immune response and eliminates disseminated EGFR-overexpressing tumors in mice. Clin Cancer Res. 2011;17(5):1033-1043.
52. Kubler K, tho Pesch C, Gehrke N, et al. Immunogenic cell death of human ovarian cancer cells induced by cytosolic poly(I:C) leads to myeloid cell maturation and activates NK cells. Eur J Immunol. 2011;41(10):3028-3039.
53. Wu CY, Yang HY, Monie A, et al. Intraperitoneal administration of poly(I:C) with polyethylenimine leads to significant antitumor immunity against murine ovarian tumors. Cancer Immunol Immunother. 2011;60(8):1085-1096.
54. Inao T, Harashima N, Monma H, et al. Antitumor effects of cytoplasmic delivery of an innate adjuvant receptor ligand, poly(I:C), on human breast cancer. Breast Cancer Res Treat. 2012;134(1):89-100.
55. Harashima N, Inao T, Imamura R, Okano S, Suda T, Harada M. Roles of the PI3K/Akt pathway and autophagy in TLR3 signaling-induced apoptosis and growth arrest of human prostate cancer cells. Cancer Immunol Immunother. 2012;61(5):667-676.
56. Steelman AJ, Li J. Poly(I:C) promotes TNFalpha/TNFR1-dependent oligodendrocyte death in mixed glial cultures. J Neuroinflammation. 2011;8:89.
57. Ngoi SM, St Rose MC, Menoret AM, et al. Presensitizing with a Toll-like receptor 3 ligand impairs CD8 T-cell effector differentiation and IL-33 responsiveness. Proc Natl Acad Sci U S A. 2012;109(26):10486-10491.
58. Morahan PS, Munson AE, Regelson W, Commerford SL, Hamilton LD. Antiviral activity and side effects of polyriboinosinic-cytidylic acid complexes as affected by molecular size. Proc Natl Acad Sci U S A. 1972;69(4):842-846.